CEMI News and Press, Chembio Diagnostics Inc. From 08/10/19

The following slide deck was published by Chembio Diagnostics, Inc. in conjunction with this Read more ...

Chembio Diagnostics, Inc. (CEMI) Q2 2019 Earnings Conference Call August 06, 2019, 16:30 ET Company Participants Philip Taylor - IR John Sperzel - President, CEO & Director Neil Goldman - EVP & CFO Conference Call Participants Per Ostlund - Craig-Hallum Capital Grou...

Chembio Diagnostics (NASDAQ: CEMI ): Q2 GAAP EPS of -$0.19 misses by $0.04 . More news on: Chembio Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

MEDFORD, N.Y., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2019. Recent Accomplishments & Highlights Achiev...

MEDFORD, N.Y., July 24, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2019 after the close of trading on Tuesday,...

Chembio Diagnostics (NASDAQ: CEMI ) will collaborate with Takeda (NYSE: TAK ) unit Shire Human Genetic Therapies to develop an point-of-care (POC) diagnostic test for an undisclosed biomarker. More news on: Chembio Diagnostics, Inc., Takeda Pharmaceutical Company Limited, Healthcare stoc...

MEDFORD, N.Y., July 18, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care (POC) diagnostics company focused on infectious diseases, today announced that it has entered into a collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subs...

MEDFORD, N.Y. , June 27, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that is has obtained a CE mark for its DPP Zika/Dengue/Chikungunya multiplex test system. Chembio’...

The FDA approves Seattle, WA-based InBios International 's ZIKV Direct 2.0 IgM Capture ELISA, the first ZIKA diagnostic test commercially available in the U.S. More news on: Chembio Diagnostics, Inc., Co-Diagnostics, Inc., Roche Holding AG, Healthcare stocks news, Read more ...

MEDFORD, N.Y., May 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Br...